Slide 1: Orion Half-Year Financial Report January–June 2023
Orion Half-Year Financial Report January–June 2023 17 July 2023
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements which involve risks and uncertainty factors. These statements are not based on historical facts but relate to the Company’s future activities and performance. They include statements about future strategies and anticipated benefits of
Slide 3: Key matters in Q2 2023
Key matters in Q2 2023 • Orion has initiated a Phase II clinical trial with tasipimidine (ODM-105) for the treatment of insomnia • Orion is preparing to start a Phase I clinical trial with ODM-212 • Update to Easyhaler® product portfolio’s peak sales potential: Easyhaler has potential to exceed EUR
Slide 4: January-June 2023 mostly in line with our expectations
January-June 2023 mostly in line with our expectations Cash flow from • Net sales in H1 2023 Net sales operating activities • Main positives: Nubeqa® and Animal Health per share • Main negatives: entacapone, Russia, dexmedetomidine and Simdax MEUR EUR • Factors explaining the decline in operating pr
Slide 5: Net sales bridge from H1 2022 to H1 2023
Net sales bridge from H1 2022 to H1 2023 1 Dexmedetomidine for human use and Simdax® 5 Other products and services (excl. Animal Health and Fermion) 2 Nubeqa® (product sales and royalty) 6 Animal Health and Fermion 3 Entacapone products 7 Exchange rates 4 Russia 5 17 July 2023 © Orion Corporation Th
Slide 6: Operating profit bridge H1 2022 to H1 2023
Operating profit bridge H1 2022 to H1 2023 ~EUR 21 million due to cost increase and changes in product mix ~EUR 36 million due to price decreases, of which significant part is explained by the fact that Orion supplied Nubeqa® to Bayer with lower price than in the comparative period Nubeqa product sa
Slide 7: Business reviews
Business reviews 300.0 Sales split in H1 2023 250.0 0% 6% 9% 17% 200.0 150.0 MEUR 22% 100.0 46% 50.0 0.0 Innovative Medicines Innovative Branded Generics & Animal Fermion Other* Branded Products Medicines Products Consumer Health Generics & Consumer Health -50.0 Health Animal Health Fermion H1 2022
Slide 8: TOP 10 products in H1 2023
TOP 10 products in H1 2023 EUR vs. Product or product portfolio million H1 2022 1. Nubeqa® 83.0 +114.3% 2. Easyhaler® product portfolio 68.2 +4.9% 3. Entacapone products* 46.8 -27.3% 4. Simdax® 15.1 -38.2% 5. Dexdomitor®, Domitor®, Domosedan®, Antisedan® 12.8 -24.6% 6. Trexan® 12.6 +72.4% 7. Dexmede
Slide 9: Innovative Medicines EUR 94.2 million (+114.0%)
Innovative Medicines EUR 94.2 million (+114.0%) • Nubeqa® sales booked by Orion EUR 83.0 million Nubeqa® sales booked by Orion1 (+114.3%) in H1 2023 50 45 • Marinus received positive CHMP opinion 40 recommending the approval of ganaxolone2 – marketing authorisation expected in the coming 35 weeks 30
Slide 10: Branded Products EUR 126.8 million (-15.2%)
Branded Products EUR 126.8 million (-15.2%) 80 • Easyhaler® product portfolio Sales split 70 68.2 continued on a growth track 65.1 64.3 1% • The decline in entacapone 60 8% mainly due to lower partner 50 46.8 sales which is mainly explained by timing of partner deliveries MEUR 40 30 • The decline in
Slide 11: Generics and Consumer Health EUR 260.3 million (-7.8%)
Generics and Consumer Health EUR 260.3 million (-7.8%) 250 • Generic competition pressing Sales split by geographic the prices and sales of Simdax® 213.3 areas and dexmedetomidine products 195.1 200 for human use • Discontinuation of business 18% 150 operations in Russia also MEUR explains the net s
Slide 12: Animal Health and Fermion
Animal Health and Fermion • Animal Health growth due to Animal Health Fermion acquisition of animal health 60 60 company VMD (Inovet) in June 50.3 2022 50 50 12.8 • Sedatives remain the largest 40 40 36.1 37.3 product group in Animal Health 30.9 • Weakening demand in animal MEUR 30 30 health market
Slide 13: Key clinical development pipeline
Key clinical development pipeline Project/compound Indication PHASE I PHASE II PHASE III REGISTRATION ARANOTE / darolutamide 1 Prostate cancer (mHSPC) ARASTEP / darolutamide 1 Prostate cancer (BCR) ODM-208 2 Prostate cancer (mCRPC) ODM-105 / tasipimidine Insomnia ODM-111 (NaV 1.8 blocker) Pain ODM-2
Slide 14: The outcome of Orion's double materiality assessment
The outcome of Orion’s double materiality assessment in accordance with Orion’s Sustainability Agenda Patient safety as a top priority Active work for a better Care for well-being Ethics at the core of our environment professionals business 1. Products that are effective, high-quality and safe to us
Slide 15: Outlook for 2023 (specified)
Outlook for 2023 (specified) Net sales Orion estimates that net sales in 2023 will be slightly higher than in 2022 without the EUR 228 million impact from ODM-208 upfront payment (net sales in 2022 without the impact of the ODM-208 upfront payment were EUR 1,113 million). Operating profit Operating
Slide 16: Basis for the outlook – key contributors
Basis for the outlook – key contributors Net sales Operating profit Nubeqa® Generic Nubeqa® Operating costs Animal Health competition Milestones* COGS** Russia Simdax® and Milestones* other declining Easyhaler® Pricing products pressure Russia * Excluding ODM-208 upfront payment * Excluding ODM-208
Slide 17: Upcoming events
Upcoming events Interim Report 1–9/2023 26/10/2023 Financial Statement Release for 2023 13/2/2024 AGM 2024 planned to be held on 20/3/2024 Interim Report 1–3/2024 25/4//2024 Half-Year Financial Report 1–6/2024 18/7/2024 Interim Report 1–9/2024 29/10/2024 17